SCHEMBL3867933

SCHEMBL3867933

C[C@H](NN(C(=O)c1cccs1)C(=O)c1ccc(C(=O)NCc2cccc(O)c2)cc1Cl)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 2/20 0.41
▸ ROCK2 O75116 4/20 0.40
▸ ROCK1 Q13464 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MT-CO2 P00403 1/20 0.38
▸ PPARG P37231 3/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ ITGAL P20701 1/20 0.37
▸ NR1H4 Q96RI1 1/20 0.37
▸ PDK1 Q15118 1/20 0.37
▸ PDK2 Q15119 1/20 0.37
▸ PDK3 Q15120 1/20 0.37
▸ PDK4 Q16654 1/20 0.37
▸ ITGB1 P05556 1/20 0.36
▸ ITGA4 P13612 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3868691 0.93 SMN1; SMN2 (0.39) BCHESMN1; SMN2MAPTPPARGNPC1
SCHEMBL3875162 0.90 BCHE (0.41) BCHEROCK2ROCK1PPARG
SCHEMBL3866583 0.90 BCHE (0.41) BCHEROCK2ROCK1PPARGNR1H4
SCHEMBL3875362 0.89 MT-CO2 (0.39) ROCK2ROCK1SMN1; SMN2MAPTMT-CO2
SCHEMBL3868742 0.89 F10 (0.43) ROCK2ROCK1SMN1; SMN2MAPTMT-CO2
SCHEMBL3866010 0.88 ROCK2 (0.41) ROCK2ROCK1SMN1; SMN2MAPTMT-CO2
SCHEMBL3869872 0.88 RAB9A (0.40) ROCK2ROCK1SMN1; SMN2MT-CO2PPARG
SCHEMBL3871174 0.88 MT-CO2 (0.40) ROCK2ROCK1MT-CO2PPARGNR1H4
SCHEMBL3873403 0.88 MT-CO2 (0.40) ROCK2ROCK1MT-CO2PPARGNR1H4
SCHEMBL3868359 0.87 ROCK2 (0.41) ROCK2ROCK1SMN1; SMN2MAPTMT-CO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491741-B2 Diaminopropionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-17 — — US disclosed
US-20070155671-A1 Diaminopropionic acid derivatives FOTOUHI NADER 2007-07-05 — — US disclosed
US-7217728-B2 Diaminopropionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2007-05-15 — — US disclosed
US-20050080119-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2005-04-14 — — US disclosed
US-6803384-B2 FOR THERAPY OF REPERFUSION INJURY HOFFMANN-LA ROCHE INC. 2004-10-12 — — US disclosed
US-20040006236-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2004-01-08 — — US disclosed
US-20020052512-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2002-05-02 — — US disclosed
US-6331640-B1 TREATMENT OF REPERFUSION INJURIES HOFFMANN-LA ROCHE INC. 2001-12-18 — — US disclosed
EP-1121342-A1 DIAMINOPROPIONIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-08-08 — — EP disclosed
WO-2000021920-A1 DIAMINOPROPIONIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006236-A1 Diaminopropionic acid derivatives AIFM1, AIFM2, HIF1A BCHE 3983/4885ROCK2 4245/4885ROCK1 3087/4885
US-20020052512-A1 Diaminopropionic acid derivatives AIFM1, AIFM2, HIF1A BCHE 3983/4885ROCK2 4245/4885ROCK1 3087/4885
US-20070155671-A1 Diaminopropionic acid derivatives AIFM1, HIF1A, AIFM2 BCHE 4042/4885ROCK2 4148/4885ROCK1 3663/4885
US-20050080119-A1 Diaminopropionic acid derivatives AIFM1, HIF1A, AIFM2 BCHE 4042/4885ROCK2 4148/4885ROCK1 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback